Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MAP3K8
REST API REST API
Homo sapiens
MAP3K8 is differentially expressed in 264 experiments: 101 organism parts: kidney, lung, ... (99 more);, 133 disease states: normal, lung adenocarcinoma, ... (131 more);, 66 cell types 284 cell lines 40 compound treatments and 62 other conditions.
Synonyms c-COT, ESTF, EST, MEKK8, COT, Tpl-2
Orthologs MAP3K8 (Gallus gallus)   MAP3K8 (Danio rerio)   A5PK86_BOVIN (Bos taurus)   Map3k8 (Mus musculus)   BCK1 (Saccharomyces cerevisiae)   Map3k8 (Rattus norvegicus)   map3k8 (Xenopus laevis)   MAP3K8 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, protein binding, cytoplasm, MAP kinase kinase kinase activity, protein tyrosine kinase activity, ATP binding, cell cycle, magnesium ion binding, nucleotide binding, kinase activity, protein serine/threonine kinase activity, signal transduction, protein kinase activity, T cell costimulation, protein phosphorylation
InterPro Term Prot_kinase_cat_dom, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession P41279, Q5T857, Q5T856, Q5T854, Q5T853
Gene-Disease Assocation LUNG CANCER
Search EB-eye ENSG00000107968
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-3529, E-GEOD-20081, E-GEOD-19639
HL-60
3
E-GEOD-24147, E-MTAB-37, E-GEOD-5258
SW480
3
E-MEXP-1014, E-GEOD-18005, E-MTAB-37
Jurkat
2
E-GEOD-1880, E-MEXP-2197
A549
2
E-GEOD-3202, E-GEOD-6013
MOLT4
2
E-MTAB-37, E-MTAB-62
278 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (39 experiments)

Factor Value U/D Experiments
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
CD19+ B cell
1
E-MEXP-1600
BDCA1+ dendritic cell
1
E-TABM-34
mononuclear cell
1
E-GEOD-7307
60 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-3860, E-MEXP-1922, E-GEOD-6872, E-GEOD-2508, ... (47 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
1
3
E-MTAB-37, E-MTAB-62, E-MEXP-231, E-GEOD-2514
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
chronic lymphocytic leukemia
2
E-MTAB-37, E-GEOD-2466
Burkitt's lymphoma
2
2
E-MTAB-37, E-GEOD-1880
colon carcinoma
2
E-MTAB-62, E-MTAB-37
melanoma
2
E-MTAB-37, E-MTAB-62
127 more value(s).


Compound treatment

studied in E-GEOD-5741, E-TABM-782, E-GEOD-3720, E-GEOD-5824, E-TABM-868, ... (30 experiments)

Factor Value U/D Experiments
none
3
7
E-GEOD-1923, E-TABM-868, E-GEOD-3140, E-GEOD-2706, E-MEXP-2285, ... (10 experiments)
placebo
2
E-MEXP-1335, E-MEXP-1327
lipopolysaccharide
1
2
E-TABM-868, E-GEOD-3140, E-GEOD-3720
resveratrol
1
E-TABM-782
baseline propofol
1
E-GEOD-4386
estradiol
1
E-GEOD-20081
34 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cancer site
studied in E-GEOD-4271

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-MTAB-37, E-GEOD-1140, E-GEOD-860, E-MEXP-1251, E-GEOD-21374, ... (9 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-20033, E-MEXP-2359, E-GEOD-4667, E-MTAB-62

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-20847, E-MTAB-108, E-GEOD-6431 ... (5 experiments)

Genotype
studied in E-GEOD-1923, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-TABM-321, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5809, E-GEOD-13073, E-GEOD-5681, E-MEXP-1446, E-GEOD-9764, ... (8 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-740, E-MEXP-1290, E-MEXP-2069, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-12108, E-GEOD-6802

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Organism
studied in E-AFMX-1, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-19703, E-GEOD-1309, E-GEOD-21750, E-GEOD-923 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343, E-GEOD-20037 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-10896

RNAi
studied in E-GEOD-3697, E-MEXP-2759

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400, E-GEOD-18995 ... (5 experiments)

Sex
studied in E-GEOD-2466

Stimulation
studied in E-GEOD-20114, E-GEOD-11886, E-GEOD-23984, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276

Treatment
studied in E-GEOD-33562, E-MEXP-973, E-GEOD-21909, E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.263 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM